tiprankstipranks
Advertisement
Advertisement
NewAmsterdam Pharma: Undervalued Growth Story With Upcoming Clinical Catalysts Supporting Buy Rating
PremiumRatingsNewAmsterdam Pharma: Undervalued Growth Story With Upcoming Clinical Catalysts Supporting Buy Rating
3M ago
NewAmsterdam Pharma initiated with a Buy at Truist
Premium
The Fly
NewAmsterdam Pharma initiated with a Buy at Truist
3M ago
NewAmsterdam Highlights Obicetrapib Progress in Investor Presentation
Premium
Company Announcements
NewAmsterdam Highlights Obicetrapib Progress in Investor Presentation
4M ago
NewAmsterdam Pharma: Late-Stage Obicetrapib Momentum, Regulatory Catalysts, and Strong Cash Position Underpin Buy Rating
PremiumRatingsNewAmsterdam Pharma: Late-Stage Obicetrapib Momentum, Regulatory Catalysts, and Strong Cash Position Underpin Buy Rating
6M ago
NewAmsterdam Pharma outlines 2026 goals after strong 2025 progress
Premium
Company Announcements
NewAmsterdam Pharma outlines 2026 goals after strong 2025 progress
6M ago
NewAmsterdam Pharma highlights 2025 achievements, 2026 priorities
Premium
The Fly
NewAmsterdam Pharma highlights 2025 achievements, 2026 priorities
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100